Product Name :
EOAI3402143
Description:
EOAI3402143 is a deubiquitinase (DUB) inhibitor, which inhibits dose-dependently inhibits Usp9x/Usp24 and Usp5.
CAS:
1699750-95-2
Molecular Weight:
503.42
Formula:
C25H28Cl2N4O3
Chemical Name:
(2E)-2-cyano-3-(3,6-dichloropyridin-2-yl)-N-(1-{4-[2-(morpholin-4-yl)ethoxy]phenyl}butyl)prop-2-enamide
Smiles :
CCCC(NC(=O)/C(=C/C1=NC(Cl)=CC=C1Cl)/C#N)C1C=CC(=CC=1)OCCN1CCOCC1
InChiKey:
IIKVQQNZHGBYGQ-KNTRCKAVSA-N
InChi :
InChI=1S/C25H28Cl2N4O3/c1-2-3-22(30-25(32)19(17-28)16-23-21(26)8-9-24(27)29-23)18-4-6-20(7-5-18)34-15-12-31-10-13-33-14-11-31/h4-9,16,22H,2-3,10-15H2,1H3,(H,30,32)/b19-16+
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
EOAI3402143 is a deubiquitinase (DUB) inhibitor, which inhibits dose-dependently inhibits Usp9x/Usp24 and Usp5.|Product information|CAS Number: 1699750-95-2|Molecular Weight: 503.42|Formula: C25H28Cl2N4O3|Chemical Name: (2E)-2-cyano-3-(3,6-dichloropyridin-2-yl)-N-(1-{4-[2-(morpholin-4-yl)ethoxy]phenyl}butyl)prop-2-enamide|Smiles: CCCC(NC(=O)/C(=C/C1=NC(Cl)=CC=C1Cl)/C#N)C1C=CC(=CC=1)OCCN1CCOCC1|InChiKey: IIKVQQNZHGBYGQ-KNTRCKAVSA-N|InChi: InChI=1S/C25H28Cl2N4O3/c1-2-3-22(30-25(32)19(17-28)16-23-21(26)8-9-24(27)29-23)18-4-6-20(7-5-18)34-15-12-31-10-13-33-14-11-31/h4-9,16,22H,2-3,10-15H2,1H3,(H,30,32)/b19-16+|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 50 mg/mL (99.{{CPDA} medchemexpress|{CPDA} Phosphatase|{CPDA} Biological Activity|{CPDA} Data Sheet|{CPDA} supplier|{CPDA} Autophagy} 32 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|EOAI3402143 retains potent Usp9x and Usp5 inhibitory activity. EOAI3402143 dose-dependently inhibits Usp9x and Usp24 activity, increases tumor cell apoptosis. Treatment of UM-2, UM-6, UM-16, and UM-76 with Usp9x inhibitor EOAI3402143 (G9) dose-dependently suppresses cell survival, while 600 nM of EOAI3402143 completely suppresses UM-2 3D colony growth when compared to untreated vehicle controls.|In Vivo:|To examine this potential, the effect of EOAI3402143 (G9) treatment is investigated on human MIAPACA2 tumor xenografts.{{Daclizumab} MedChemExpress|{Daclizumab} Interleukin Related|{Daclizumab} Protocol|{Daclizumab} Purity|{Daclizumab} supplier|{Daclizumab} Epigenetic Reader Domain} Human MIAPACA2 cells are injected subcutaneously into NSG mice.PMID:23710097 Primary tumor development is monitored by caliper measurements, and once measurable, mice are separated into two groups and are treated with either vehicle control (PEG300/DMSO) or G9 at 15 mg/kg. Tumor growth, animal weight, behavior, and mobility are monitored during treatment. In parallel, murine 8041 tumors are also established and subjected to similar G9 treatment and tumor monitoring regimen as the human MIAPACA2 xenografts. Consistent with the in vitro findings, Usp9x inhibition results in the suppression of tumor growth in human tumor xenografts, but any significant effect on the growth of 8041 tumors xenografts is not observed, although the Usp9x activity is inhibited effectively by EOAI3402143 treatment in both human MIAPACA2 and mouse 8041 xenograft tumors.|Products are for research use only. Not for human use.|